Oncoepigenomics: making histone lysine methylation count

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology

Background:

• Histone lysine methylation is increasingly linked to diseases including schizophrenia, diabetes, and cancers.
• Epigenetic alterations, particularly histone modifications, are critical drivers of disease pathology.
• Targeting enzymes involved in histone methylation offers a promising therapeutic strategy.

Purpose of the Study:

• To provide a comprehensive review of current advancements in targeting histone lysine methyltransferases (KMTs) and demethylases (KDMs).
• To highlight the role of KMTs and KDMs in tumor growth and progression.
• To discuss the development of small molecules designed to modulate these epigenetic enzymes.

Main Methods:

• Literature review of recent studies on histone lysine methylation.
• Analysis of the role of KMTs and KDMs in various disease models, with a focus on cancer.
• Survey of small molecule inhibitors and activators targeting KMTs and KDMs.

Main Results:

• KMTs and KDMs are crucial regulators of gene expression with significant roles in disease pathogenesis.
• Dysregulation of histone methylation is a hallmark of numerous human cancers, influencing tumor initiation and metastasis.
• Several small molecules targeting KMTs and KDMs are in preclinical and clinical development for cancer therapy.

Conclusions:

• Targeting KMTs and KDMs represents a significant frontier in epigenetic therapy for diseases like cancer.
• Further research into the precise roles and modulation of these enzymes will accelerate the development of novel therapeutics.
• Small molecule modulators offer a viable approach to correct aberrant epigenetic states in disease.